US Pharma MarketingMakary’s FDA reforms ‘continue to move forward’ despite leadership turmoil
As the FDA adjusts to life without Marty Makary, M.D., Fierce has learned that the numerous policy reforms he put in motion are set to remain intact, including the controversial Commissioner’s Nati As the FDA adjusts to life without Marty Makary, M.D., who resigned as commissioner two weeks ago, the numerous policy reforms he put in motion remain intact, including the controversial Commissioner’s National Priority Voucher (CNPV) program. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug…
As the FDA adjusts to life without Marty Makary, M.D., who resigned as commissioner two weeks ago, the numerous policy reforms he put in motion remain intact, including the controversial Commissioner’s National Priority Voucher (CNPV) program.
Source: FierceBiotech